Literature DB >> 7761412

The protein deficient in Lowe syndrome is a phosphatidylinositol-4,5-bisphosphate 5-phosphatase.

X Zhang1, A B Jefferson, V Auethavekiat, P W Majerus.   

Abstract

Lowe syndrome, also known as oculocerebrorenal syndrome, is caused by mutations in the X chromosome-encoded OCRL gene. The OCRL protein is 51% identical to inositol polyphosphate 5-phosphatase II (5-phosphatase II) from human platelets over a span of 744 aa, suggesting that OCRL may be a similar enzyme. We engineered a construct of the OCRL cDNA that encodes amino acids homologous to the platelet 5-phosphatase for expression in baculovirus-infected Sf9 insect cells. This cDNA encodes aa 264-968 of the OCRL protein. The recombinant protein was found to catalyze the reactions also carried out by platelet 5-phosphatase II. Thus OCRL converts inositol 1,4,5-trisphosphate to inositol 1,4-bisphosphate, and it converts inositol 1,3,4,5-tetrakisphosphate to inositol 1,3,4-trisphosphate. Most important, the enzyme converts phosphatidylinositol 4,5-bisphosphate to phosphatidylinositol 4-phosphate. The relative ability of OCRL to catalyze the three reactions is different from that of 5-phosphatase II and from that of another 5-phosphatase isoenzyme from platelets, 5-phosphatase I. The recombinant OCRL protein hydrolyzes the phospholipid substrate 10- to 30-fold better than 5-phosphatase II, and 5-phosphatase I does not cleave the lipid at all. We also show that OCRL functions as a phosphatidylinositol 4,5-bisphosphate 5-phosphatase in OCRL-expressing Sf9 cells. These results suggest that OCRL is mainly a lipid phosphatase that may control cellular levels of a critical metabolite, phosphatidylinositol 4,5-bisphosphate. Deficiency of this enzyme apparently causes the protean manifestations of Lowe syndrome.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7761412      PMCID: PMC41805          DOI: 10.1073/pnas.92.11.4853

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  24 in total

1.  Organic-aciduria, decreased renal ammonia production, hydrophthalmos, and mental retardation; a clinical entity.

Authors:  C U LOWE; M TERREY; E A MacLACHLAN
Journal:  AMA Am J Dis Child       Date:  1952-02

2.  Isolation of a phosphomonoesterase from human platelets that specifically hydrolyzes the 5-phosphate of inositol 1,4,5-trisphosphate.

Authors:  T M Connolly; T E Bross; P W Majerus
Journal:  J Biol Chem       Date:  1985-07-05       Impact factor: 5.157

3.  Gelsolin-polyphosphoinositide interaction. Full expression of gelsolin-inhibiting function by polyphosphoinositides in vesicular form and inactivation by dilution, aggregation, or masking of the inositol head group.

Authors:  P A Janmey; T P Stossel
Journal:  J Biol Chem       Date:  1989-03-25       Impact factor: 5.157

4.  The actin-binding protein profilin binds to PIP2 and inhibits its hydrolysis by phospholipase C.

Authors:  P J Goldschmidt-Clermont; L M Machesky; J J Baldassare; T D Pollard
Journal:  Science       Date:  1990-03-30       Impact factor: 47.728

5.  Evidence that the inositol phospholipids are necessary for exocytosis. Loss of inositol phospholipids and inhibition of secretion in permeabilized cells caused by a bacterial phospholipase C and removal of ATP.

Authors:  D A Eberhard; C L Cooper; M G Low; R W Holz
Journal:  Biochem J       Date:  1990-05-15       Impact factor: 3.857

6.  Phosphatidylinositol 3-phosphate is present in normal and transformed fibroblasts and is resistant to hydrolysis by bovine brain phospholipase C II.

Authors:  D L Lips; P W Majerus; F R Gorga; A T Young; T L Benjamin
Journal:  J Biol Chem       Date:  1989-05-25       Impact factor: 5.157

7.  Inositol phospholipids activate plasma membrane ATPase in plants.

Authors:  A R Memon; Q Y Chen; W F Boss
Journal:  Biochem Biophys Res Commun       Date:  1989-08-15       Impact factor: 3.575

8.  Polyamines and neomycin inhibit the purified plasma-membrane Ca2+ pump by interacting with associated polyphosphoinositides.

Authors:  L Missiaen; F Wuytack; L Raeymaekers; H De Smedt; R Casteels
Journal:  Biochem J       Date:  1989-08-01       Impact factor: 3.857

9.  Mechanism of protein kinase C activation by phosphatidylinositol 4,5-bisphosphate.

Authors:  M H Lee; R M Bell
Journal:  Biochemistry       Date:  1991-01-29       Impact factor: 3.162

10.  The inositol trisphosphate phosphomonoesterase of the human erythrocyte membrane.

Authors:  C P Downes; M C Mussat; R H Michell
Journal:  Biochem J       Date:  1982-04-01       Impact factor: 3.857

View more
  74 in total

1.  Mouse model for Lowe syndrome/Dent Disease 2 renal tubulopathy.

Authors:  Susan P Bothwell; Emily Chan; Isa M Bernardini; Yien-Ming Kuo; William A Gahl; Robert L Nussbaum
Journal:  J Am Soc Nephrol       Date:  2010-12-23       Impact factor: 10.121

2.  OCRL1 mutations in patients with Dent disease phenotype in Japan.

Authors:  Takashi Sekine; Kandai Nozu; Rashmi Iyengar; Xue Jun Fu; Masafumi Matsuo; Ryojiro Tanaka; Kazumoto Iijima; Emiko Matsui; Yutaka Harita; Jun Inatomi; Takashi Igarashi
Journal:  Pediatr Nephrol       Date:  2007-03-24       Impact factor: 3.714

3.  A PH domain within OCRL bridges clathrin-mediated membrane trafficking to phosphoinositide metabolism.

Authors:  Yuxin Mao; Daniel M Balkin; Roberto Zoncu; Kai S Erdmann; Livia Tomasini; Fenghua Hu; Moonsoo M Jin; Michael E Hodsdon; Pietro De Camilli
Journal:  EMBO J       Date:  2009-06-18       Impact factor: 11.598

4.  Novel OCRL1 gene mutations in six Chinese families with Lowe syndrome.

Authors:  Yan Gao; Fang Jiang; Zhi-Ying Ou
Journal:  World J Pediatr       Date:  2016-04-08       Impact factor: 2.764

5.  The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-triphosphate 5-phosphatase.

Authors:  J E Damen; L Liu; P Rosten; R K Humphries; A B Jefferson; P W Majerus; G Krystal
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-20       Impact factor: 11.205

6.  Maternal de novo triple mosaicism for two single OCRL nucleotide substitutions (c.1736A>T, c.1736A>G) in a Lowe syndrome family.

Authors:  Markus Draaken; Carmen A Giesen; Anne L Kesselheim; Ronald Jabs; Stefan Aretz; Monika Kugaudo; Krystyna H Chrzanowska; Malgorzata Krajewska-Walasek; Michael Ludwig
Journal:  Hum Genet       Date:  2011-01-12       Impact factor: 4.132

7.  A role of the Lowe syndrome protein OCRL in early steps of the endocytic pathway.

Authors:  Kai S Erdmann; Yuxin Mao; Heather J McCrea; Roberto Zoncu; Sangyoon Lee; Summer Paradise; Jan Modregger; Daniel Biemesderfer; Derek Toomre; Pietro De Camilli
Journal:  Dev Cell       Date:  2007-09       Impact factor: 12.270

8.  SopB, a protein required for virulence of Salmonella dublin, is an inositol phosphate phosphatase.

Authors:  F A Norris; M P Wilson; T S Wallis; E E Galyov; P W Majerus
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

9.  The 5-phosphatase OCRL mediates retrograde transport of the mannose 6-phosphate receptor by regulating a Rac1-cofilin signalling module.

Authors:  Vanessa A van Rahden; Kristina Brand; Juliane Najm; Joerg Heeren; Suzanne R Pfeffer; Thomas Braulke; Kerstin Kutsche
Journal:  Hum Mol Genet       Date:  2012-08-19       Impact factor: 6.150

10.  X-inactivation analysis of embryonic lethality in Ocrl wt/-; Inpp5b-/- mice.

Authors:  David J Bernard; Robert L Nussbaum
Journal:  Mamm Genome       Date:  2010-02-27       Impact factor: 2.957

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.